GlassScriptPhysician profile
Benjamin G Horn
NPI 1801843032
$4,476.44
in general payments reported to CMS, 2019-2025
41 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $156 · 2021: $329 · 2022: $659 · 2023: $681 · 2024: $1,054 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,155.90 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $825.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $403.56 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $342.26 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $292.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.53 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Novartis Pharmaceuticals Corporation | $235.35 | 2019-2025 | |
| Amgen INC. | $163.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $160.33 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $157.71 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.31 | 2021-2025 | |
| Astellas Pharma US INC | $128.00 | 2020-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $121.42 | 2020-2024 | Eliquis |
| Antares Pharma, INC. | $103.23 | 2024-2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $95.93 | 2023-2025 | Quviviq, Quviviq |
| Exact Sciences Corporation | $83.67 | 2023-2025 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.